<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070031</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000329917</org_study_id>
    <secondary_id>MSKCC-03056</secondary_id>
    <secondary_id>PHARMACIA-EDOABC-4439-001</secondary_id>
    <nct_id>NCT00070031</nct_id>
  </id_info>
  <brief_title>Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy</brief_title>
  <official_title>A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as edotecarin use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well edotecarin works in treating women with&#xD;
      locally advanced or metastatic breast cancer that has not responded to previous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the antitumor activity of edotecarin in women with anthracycline- and&#xD;
           taxane-refractory or chemoresistant locally advanced or metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to tumor response and duration of response in patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the clinical benefit of this drug in these patients.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive edotecarin IV over 1 hour on day 1. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 31-65 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edotecarin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed primary adenocarcinoma of the breast&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Not amenable to surgery or radiotherapy with curative intent&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR 10 mm by CT scan&#xD;
&#xD;
               -  Not previously irradiated&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Previously treated with anthracycline and concurrent or sequential taxane therapy&#xD;
&#xD;
                    -  Refractory to the most recent taxane-based chemotherapy, defined as 1 of the&#xD;
                       following:&#xD;
&#xD;
                         -  Progressive disease during therapy or within 4 months of the last dose&#xD;
                            with or without documented response for advanced disease&#xD;
&#xD;
                         -  Progressive disease within 6 months of completing taxane-based&#xD;
                            chemotherapy as neoadjuvant therapy&#xD;
&#xD;
               -  Resistant to prior chemotherapy, as defined by progressive disease within 6&#xD;
                  months of completing prior chemotherapy for advanced disease&#xD;
&#xD;
          -  No known brain metastases or carcinomatous meningitis* NOTE: *Baseline CT scan or MRI&#xD;
             of the brain required if there is clinical suspicion of CNS metastases&#xD;
&#xD;
          -  No spinal cord compression&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN (5 times ULN if liver involvement secondary to&#xD;
             tumor is present)&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50% or ULN by echocardiogram or MUGA&#xD;
&#xD;
          -  None of the following within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Deep vein thrombosis or other significant thromboembolic event&#xD;
&#xD;
          -  No ongoing cardiac dysrhythmias grade 2 or greater&#xD;
&#xD;
          -  No atrial fibrillation of any grade&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism within the past 6 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  No partial or complete bowel obstruction&#xD;
&#xD;
          -  No chronic diarrhea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that would preclude study participation or confound study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biological response modifiers&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No other concurrent granulocyte colony-stimulating factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No prior topoisomerase I inhibitors&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for advanced disease&#xD;
&#xD;
          -  No prior high-dose chemotherapy that required hematopoietic stem cell rescue&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior adjuvant hormonal therapy or hormonal therapy for advanced/metastatic disease&#xD;
             allowed provided that therapy is discontinued before study entry&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy during and for 5 days after study treatment&#xD;
&#xD;
               -  Palliative radiotherapy allowed provided no more than 20% of the bone marrow is&#xD;
                  involved&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No coronary/peripheral artery bypass graft within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy (except alopecia or neurotoxicity)&#xD;
&#xD;
          -  At least 4 weeks since any other prior therapy&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No concurrent enrollment on another clinical trial&#xD;
&#xD;
          -  No other concurrent approved or investigational anticancer treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D. Seidman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clifford A. Hudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

